ArticleNature2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.Cell reports. Medicine · 2025Trial
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.Biomaterials · 2026Article
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.HemaSphere · 2026Article
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.Nature communications · 2026Article
- Cell surface ADGRG1 and CD86 expression identifies antitumor CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy.Cancers · 2026Review
- CXCR6+ CD127- Tr1 cells balance immunity and persistence in Plasmodium falciparum infection.The Journal of clinical investigation · 2026Article
- Epigenetic landscape, key transcriptional regulators, and in vivo identification of human Tr1 cells.Science advances · 2026Article
- SHIP1 is required for T cell surveillance of occult malignancies.Cellular and molecular life sciences : CMLS · 2026Article
- Modular Vaccine Robots for Spatiotemporal Programming of the CD4Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- CD4Science (New York, N.Y.) · 2026Article
- mRNA vaccines engage unconventional pathways in CD8Nature · 2026Article
- Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.Materials today. Bio · 2026Article
- "Ferroptosis-immune" cycle: Research progress of tumor microenvironment responsive nanomaterials in the treatment of pancreatic cancer.iScience · 2026Review
- Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.Science immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Hussein SultanDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-4067-8169
Yoshiko TakeuchiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-2637-7696
Jeffrey P WardDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-9707-895X
Naveen SharmaDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1343-3230
Tian-Tian LiuDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-9377-9938
Vladimir SukhovDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Maria FirulyovaAlmazov National Medical Research Centre, St. Petersburg, Russia.
Yuang SongDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Samuel AmehDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Simone BrioschiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Darya KhantakovaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-2579-5140
Cora D ArthurDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
J Michael WhiteDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-5110-6567
Heather KohlmillerDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Andres M SalazarOncovir Inc., Washington, DC, USA.
Robert BurnsNatera Inc., Austin, TX, USA.
Helio A CostaNatera Inc., Austin, TX, USA.
Kelly D MoynihanAsher Biotherapeutics, South San Francisco, CA, USA.
Yik Andy YeungAsher Biotherapeutics, South San Francisco, CA, USA.
Ivana DjureticAsher Biotherapeutics, South San Francisco, CA, USA.
Ton N SchumacherNetherlands Cancer Institute, Oncode Institute, Amsterdam, Leiden University, Leiden, Netherlands.
Kathleen C F SheehanDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-5222-4987
James P AllisonDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kenneth M MurphyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-3505-9630
Maxim N ArtyomovDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-1133-4212
Robert D SchreiberDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. rdschreiber@wustl.edu.ORCID 0000-0003-1590-2341
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MWashington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI David W Piston · 2018 to 2026
$7.6MMolecular Basis of cDC1 DevelopmentR01AI162643 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2025
$2.8MFunction of Wdfy4 in cross-presentation and immunityR01AI150297 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2019 to 2023
$2.5MUnderstanding the Mechanisms of DC Licensing in CD8 T Cell PrimingR01CA248919 · NCI · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2025
$2.3MDEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPYR01CA190700 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 2015 to 2019
$2.1MSupplement: Cancer-Cell and T-cell Dependent Regulation of Tumor Associated MacrophagesK08CA245215 · NCI · WASHINGTON UNIVERSITY · PI WARD, JEFFREY P · 2019 to 2023
$1.0MMechanism of c-MYC repression by IRF8 in myeloid lineagesR21AI164142 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2022
$433kTranscriptional basis of embryonic macrophage developmentR21AI163421 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2023
$430kNCI NIH HHS K08 CA245215NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA190700NCI NIH HHS R01 CA248919NCI NIH HHS T32 CA009547NIAID NIH HHS R01 AI150297NIAID NIH HHS R01 AI162643NIAID NIH HHS R21 AI163421NIAID NIH HHS R21 AI164142NIAMS NIH HHS P30 AR073752
Abstract
CD4
Indexed as
Antigens, NeoplasmCD4-Positive T-LymphocytesCytotoxicity, ImmunologicImmunotherapyNeoplasmsT-Lymphocytes, RegulatoryAnimalsCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorChemokine CCL5Dendritic CellsFemaleGranzymesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIAntigens, NeoplasmCancer VaccinesChemokine CCL5GranzymesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInterleukin-10Lilrb4 protein, mouseMembrane GlycoproteinsReceptors, Immunologic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.